Zentalis Pharmaceuticals (NASDAQ:ZNTL) Receives Buy Rating from Guggenheim

Guggenheim reissued their buy rating on shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) in a report issued on Friday morning,Benzinga reports. They currently have a $6.00 target price on the stock.

Separately, Wells Fargo & Company initiated coverage on shares of Zentalis Pharmaceuticals in a research report on Tuesday, March 17th. They issued an “equal weight” rating and a $5.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Zentalis Pharmaceuticals presently has an average rating of “Hold” and an average target price of $5.17.

Zentalis Pharmaceuticals Stock Down 21.3%

ZNTL stock opened at $2.10 on Friday. The business has a fifty day moving average of $2.57 and a two-hundred day moving average of $1.94. The stock has a market cap of $151.73 million, a price-to-earnings ratio of -1.11 and a beta of 1.71. Zentalis Pharmaceuticals has a 52-week low of $1.01 and a 52-week high of $3.95.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its quarterly earnings results on Thursday, March 26th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.08). As a group, sell-side analysts anticipate that Zentalis Pharmaceuticals will post -2.42 EPS for the current year.

Insider Buying and Selling at Zentalis Pharmaceuticals

In other Zentalis Pharmaceuticals news, insider Vincent Vultaggio sold 29,951 shares of the business’s stock in a transaction dated Friday, February 6th. The shares were sold at an average price of $2.43, for a total transaction of $72,780.93. Following the sale, the insider directly owned 156,779 shares in the company, valued at $380,972.97. This represents a 16.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Group Walters purchased 6,459,973 shares of Zentalis Pharmaceuticals stock in a transaction dated Wednesday, December 31st. The shares were acquired at an average cost of $1.20 per share, for a total transaction of $7,751,967.60. Following the transaction, the insider directly owned 13,509,973 shares of the company’s stock, valued at approximately $16,211,967.60. This represents a 91.63% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders sold a total of 46,617 shares of company stock worth $113,417 in the last quarter. Company insiders own 1.90% of the company’s stock.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. Sivia Capital Partners LLC purchased a new position in Zentalis Pharmaceuticals in the 4th quarter valued at approximately $27,000. Qube Research & Technologies Ltd acquired a new stake in shares of Zentalis Pharmaceuticals in the second quarter valued at $37,000. Corient Private Wealth LLC purchased a new position in Zentalis Pharmaceuticals in the second quarter valued at $41,000. Voleon Capital Management LP acquired a new position in Zentalis Pharmaceuticals during the 3rd quarter worth $41,000. Finally, SG Americas Securities LLC grew its stake in Zentalis Pharmaceuticals by 35.3% during the 3rd quarter. SG Americas Securities LLC now owns 31,579 shares of the company’s stock worth $48,000 after purchasing an additional 8,236 shares in the last quarter.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.